These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29128865)

  • 21. Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.
    Chen D; Wen X; Song YS; Rhee YY; Lee TH; Cho NY; Han SW; Kim TY; Kang GH
    Clin Epigenetics; 2016; 8():36. PubMed ID: 27051466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
    Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant promoter methylation of RASSF1A gene may be correlated with colorectal carcinogenesis: a meta-analysis.
    Wang HL; Zhang Y; Liu P; Zhou PY
    Mol Biol Rep; 2014 Jun; 41(6):3991-9. PubMed ID: 24566684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
    Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
    Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promoter methylation of the RASSF1A gene may contribute to colorectal cancer susceptibility: a meta-analysis of cohort studies.
    Wang HL; Liu P; Zhou PY; Zhang Y
    Ann Hum Genet; 2014 May; 78(3):208-16. PubMed ID: 24621386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
    Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
    Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor.
    Ohshima J; Haruta M; Fujiwara Y; Watanabe N; Arai Y; Ariga T; Okita H; Koshinaga T; Oue T; Hinotsu S; Nakadate H; Horie H; Fukuzawa M; Kaneko Y
    Pediatr Blood Cancer; 2012 Sep; 59(3):499-505. PubMed ID: 22457227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Association between RIPK4 relative copy number and prognosis of colorectal cancer patient after oxaliplatin-based chemotherapy].
    Peng K; Lin M; Wei Q; Li H; Zhang C; Xie R; Liu Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Nov; 18(11):1111-4. PubMed ID: 26616804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NKX6.1 hypermethylation predicts the outcome of stage II colorectal cancer patients undergoing chemotherapy.
    Chang SY; Kuo CC; Wu CC; Hsiao CW; Hu JM; Hsu CH; Chou YC; Shih YL; Lin YW
    Genes Chromosomes Cancer; 2018 May; 57(5):268-277. PubMed ID: 29363224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
    Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
    Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. K-ras mutations and RASSF1A promoter methylation in colorectal cancer.
    van Engeland M; Roemen GM; Brink M; Pachen MM; Weijenberg MP; de Bruïne AP; Arends JW; van den Brandt PA; de Goeij AF; Herman JG
    Oncogene; 2002 May; 21(23):3792-5. PubMed ID: 12032847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance.
    Lee SM; Lee WK; Kim DS; Park JY
    Mol Med Rep; 2012 Jan; 5(1):239-44. PubMed ID: 21971684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between RASSF1A promoter methylation and renal cell cancer susceptibility: a meta-analysis.
    Huang YQ; Guan H; Liu CH; Liu DC; Xu B; Jiang L; Lin ZX; Chen M
    Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma.
    Lin JC; Wu YC; Wu CC; Shih PY; Wang WY; Chien YC
    Ann Hepatol; 2015; 14(4):494-504. PubMed ID: 26019036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics.
    Shao C; Dai W; Li H; Tang W; Jia S; Wu X; Luo Y
    PLoS One; 2017; 12(2):e0171676. PubMed ID: 28207831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community.
    Protásio BM; Matutino A; Lage LV; Santana I; Ramos R; Sabbaga J; Capareli F; Saragiotto D; Riechelmann R; Hoff PM
    Clin Colorectal Cancer; 2017 Mar; 16(1):65-72. PubMed ID: 27515842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. β-catenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients.
    Schirosi L; Mazzotta A; Opinto G; Pinto R; Graziano G; Tommasi S; Fucci L; Simone G; Mangia A
    Oncotarget; 2016 Oct; 7(42):67841-67850. PubMed ID: 27765918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma.
    Kawai Y; Sakano S; Suehiro Y; Okada T; Korenaga Y; Hara T; Naito K; Matsuyama H; Hinoda Y
    Ann Oncol; 2010 Aug; 21(8):1612-1617. PubMed ID: 20038516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.